Apthera Inc.

Apthera was formed two years ago to further develop NeuVax, an investigational therapeutic cancer vaccine. NeuVax, which combines the T-cell peptide E75 with GM-CSF, is poised to enter Phase III testing in early-stage breast cancer patients to prevent recurrence of the disease and is also in early trials in prostate cancer,